Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Absence of exacerbation of myocardial stunning in anesthetized dogs treated with KAD-1229, a novel hypoglycemic agent
Autore:
Ichikawa, K; Maruyama, K; Murakami, M; Tsuji, A; Yamato, T; Kusama, H; Kojima, M;
Indirizzi:
Kissei Pharmaceut Co Ltd, Pharmacol Labs, Pharmacol R&D, Nagano 3998304, Japan Kissei Pharmaceut Co Ltd Nagano Japan 3998304 R&D, Nagano 3998304, Japan
Titolo Testata:
EUROPEAN JOURNAL OF PHARMACOLOGY
fascicolo: 3, volume: 431, anno: 2001,
pagine: 331 - 338
SICI:
0014-2999(20011123)431:3<331:AOEOMS>2.0.ZU;2-4
Fonte:
ISI
Lingua:
ENG
Soggetto:
K+ CHANNEL; SULFONYLUREAS; INFARCTION; MORTALITY; RECEPTOR;
Keywords:
KAD-1229; glibenclamide; myocardial stunning; sulfonylurea receptors; diabetes mellitus;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
25
Recensione:
Indirizzi per estratti:
Indirizzo: Ichikawa, K Kissei Pharmaceut Co Ltd, Pharmacol Labs, Pharmacol R&D, 4365-1 Kashiwabara, Nagano 3998304, Japan Kissei Pharmaceut Co Ltd 4365-1 Kashiwabara Nagano Japan 3998304
Citazione:
K. Ichikawa et al., "Absence of exacerbation of myocardial stunning in anesthetized dogs treated with KAD-1229, a novel hypoglycemic agent", EUR J PHARM, 431(3), 2001, pp. 331-338

Abstract

The effect of (+)-momocalcium bis[(2S,3a,7a-cis)-alpha -benzylhexahydro-gamma -oxo-2-isoindolinebutyrate]dihydrate (KAD-1229), a novel hypoglycemic agent with a chemical structure different from that of the sulfonylureas, onmyocardial stunning was assessed in anesthetized dogs by comparison with that of glibenclamide, a sulfonylurea. Even though their hypoglycemic effects were of similar magnitude, glibenclamide (1 mg/kg, i.v.), but not KAD-1229, exacerbated the myocardial stunning induced by occlusion/reperfusion of the descending coronary artery. In a receptor-binding experiment, unlabeledglibenclamide completely inhibited [H-1]glibenclamide binding to the myocardium, but KAD-1229 did not. These results suggest that the difference in binding properties of KAD-1229 and glibenclamide toward cardiac sulfonylureareceptors is one of the causes of their different effects on myocardial stunning. It is likely that KAD-1229 is highly specific for pancreatic sulfonylurea receptors and is speculated to be a safer hypoglycemic agent than, at least, glibenclamide. (C) 2001 Elsevier Science B.V. All rights reserved.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 01/10/20 alle ore 15:48:24